Altered cortico-striatal crosstalk underlies object recognition memory deficits in the sub-chronic phencyclidine model of schizophrenia.
Aman Asif-Malik, Daniel Dautan, Andrew M J Young, Todor V Gerdjikov
Brain Structure and Function September 2017 DOI: 10.1007/s00429-017-1393-3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study in rodents Peer reviewed |
|---|---|
| Population | PCP-treated rats |
| Intervention | Phencyclidine (PCP) |
| Keywords | Medial prefrontal cortex Neurophysiology Novel object recognition Nucleus accumbens Phencyclidine Schizophrenia |
| Key findings | PCP treatment impaired novel object recognition performance and was accompanied by reduced tonic NAc neuronal activity, desynchronized mPFC-NAc cross-activation, and loss of the normal increase in mPFC and NAc activity during novel-object exploration. The authors argue these cortico-striatal network adaptations underlie PCP-induced cognitive deficits and may contribute to cognitive abnormalities in schizophrenia. |
Abstract
The neural mechanisms underlying cognitive deficits in schizophrenia are poorly understood. Sub-chronic treatment with the NMDA antagonist phencyclidine (PCP) produces cognitive abnormalities in rodents that reliably model aspects of the neurocognitive alterations observed in schizophrenia. Given that network activity across regions encompassing medial prefrontal cortex (mPFC) and nucleus accumbens (NAc) plays a significant role in motivational and cognitive tasks, we measured activity across cortico-striatal pathways in PCP-treated rats to characterize neural enabling and encoding of task performance in a novel object recognition task. We found that PCP treatment impaired task performance and concurrently (1) reduced tonic NAc neuronal activity, (2) desynchronized cross-activation of mPFC and NAc neurons, and (3) prevented the increase in mPFC and NAc neural activity associated with the exploration of a novel object in relation to a familiar object. Taken together, these observations reveal key neuronal and network-level adaptations underlying PCP-induced cognitive deficits, which may contribute to the emergence of cognitive abnormalities in schizophrenia.
Citations in the library
Cites 6
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model. Behavioural Brain Research October 1, 2016
- Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. The International Journal of Neuropsychopharmacology October 31, 2014
- Phencyclidine (PCP)-Induced Disruption in Cognitive Performance is Gender-Specific and Associated with a Reduction in Brain-Derived Neurotrophic Factor (BDNF) in Specific Regions of the Female Rat Brain Journal of Molecular Neuroscience September 18, 2010
and 1 more in the library